ATE450266T1 - Parapocken-viren in kombination mit klassischen zytotoxischen chemotherapeutika als biochemotherapie zur behandlung von krebs - Google Patents

Parapocken-viren in kombination mit klassischen zytotoxischen chemotherapeutika als biochemotherapie zur behandlung von krebs

Info

Publication number
ATE450266T1
ATE450266T1 AT06806214T AT06806214T ATE450266T1 AT E450266 T1 ATE450266 T1 AT E450266T1 AT 06806214 T AT06806214 T AT 06806214T AT 06806214 T AT06806214 T AT 06806214T AT E450266 T1 ATE450266 T1 AT E450266T1
Authority
AT
Austria
Prior art keywords
biochemotherapy
cancer
treatment
combination
cytotoxic chemotherapeutics
Prior art date
Application number
AT06806214T
Other languages
English (en)
Inventor
Olaf Weber
Original Assignee
Aicuris Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37654955&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE450266(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aicuris Gmbh & Co Kg filed Critical Aicuris Gmbh & Co Kg
Application granted granted Critical
Publication of ATE450266T1 publication Critical patent/ATE450266T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT06806214T 2005-11-24 2006-10-12 Parapocken-viren in kombination mit klassischen zytotoxischen chemotherapeutika als biochemotherapie zur behandlung von krebs ATE450266T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05025600 2005-11-24
PCT/EP2006/009855 WO2007059821A1 (en) 2005-11-24 2006-10-12 Parapoxviruses in combination with classical cytotoxic chemotherapeutic agents as biochemotherapy for the treatment of cancer

Publications (1)

Publication Number Publication Date
ATE450266T1 true ATE450266T1 (de) 2009-12-15

Family

ID=37654955

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06806214T ATE450266T1 (de) 2005-11-24 2006-10-12 Parapocken-viren in kombination mit klassischen zytotoxischen chemotherapeutika als biochemotherapie zur behandlung von krebs

Country Status (14)

Country Link
US (1) US7897159B2 (de)
EP (1) EP1951274B1 (de)
JP (1) JP5164849B2 (de)
CN (1) CN101312737B (de)
AR (1) AR057922A1 (de)
AT (1) ATE450266T1 (de)
CA (1) CA2630833C (de)
DE (1) DE602006010902D1 (de)
DK (1) DK1951274T3 (de)
ES (1) ES2335308T3 (de)
PL (1) PL1951274T3 (de)
PT (1) PT1951274E (de)
TW (1) TWI415617B (de)
WO (1) WO2007059821A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101313702B1 (ko) 2005-02-03 2013-10-04 와이어쓰 제피티니브 및/또는 에를로티니브 내성암 치료용 약제학적 조성물
EP1942937A1 (de) 2005-11-04 2008-07-16 Wyeth Antitumor-kombinationen mit mtor-hemmer, herceptin und/oder hki-272
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
BRPI0914790A2 (pt) 2008-06-17 2015-10-20 Wyeth Llc uso de um composto de vinorelbina e um composto de hki-272, composição farmacêutica e produto e kit para o tratamento de neoplasma
US8669273B2 (en) 2008-08-04 2014-03-11 Wyeth Llc Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
DK3000467T3 (da) 2009-04-06 2023-03-27 Wyeth Llc Behandling med neratinib mod brystkræft

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3816139A1 (de) 1987-10-17 1989-04-27 Bayer Ag Verfahren zur herstellung von paramunitaetsinducern
DE19922407A1 (de) * 1999-05-14 2000-11-16 Bayer Ag Organ-, gewebs- und zellspezifisches Immuntherapeutikum für chronische virale Infektionen, sowie entzündliche, degenerative und proliferative Erkrankungen insbesondere der Leber sowie Krebs auf der Basis von rekombinantem Parapoxvirus
UY26832A1 (es) * 2000-07-11 2002-01-31 Bayer Ag Uso de cepas de parapoxvirus ovis para la fabricacion de medicamentos antivirales y medicamentos contra el cancer
AR035227A1 (es) * 2001-02-20 2004-05-05 Oncolytics Biotech Inc Uso de un agente quimioterapeutico para la manufactura de un medicamento para la sensibilizacion de celulas neoplasicas resistentes a agentes quimioterapeuticos con reovirus
NZ512341A (en) * 2001-06-13 2004-02-27 Bayer Ag Polynucleotides between 15 and 100 base pairs in length coding for parapoxvirus ovis (PPVO)/vaccinia virus recombinant (VVOV) viral genome fragments
KR20120002613A (ko) * 2002-08-12 2012-01-06 제네렉스, 인코포레이티드 폭스바이러스 및 암과 관련된 방법 및 조성물

Also Published As

Publication number Publication date
PT1951274E (pt) 2009-12-14
TW200738250A (en) 2007-10-16
CN101312737A (zh) 2008-11-26
TWI415617B (zh) 2013-11-21
JP2009517347A (ja) 2009-04-30
CN101312737B (zh) 2012-11-14
JP5164849B2 (ja) 2013-03-21
EP1951274A1 (de) 2008-08-06
HK1117427A1 (en) 2009-01-16
US7897159B2 (en) 2011-03-01
DK1951274T3 (da) 2010-02-01
PL1951274T3 (pl) 2010-05-31
CA2630833A1 (en) 2007-05-31
EP1951274B1 (de) 2009-12-02
US20090035269A1 (en) 2009-02-05
WO2007059821A1 (en) 2007-05-31
CA2630833C (en) 2015-01-06
DE602006010902D1 (de) 2010-01-14
ES2335308T3 (es) 2010-03-24
AR057922A1 (es) 2007-12-26

Similar Documents

Publication Publication Date Title
LTPA2020006I1 (lt) GDF gaudyklės, skirtos naudoti anemijos gydymui
ATE547102T1 (de) Carbolin-derivate zur behandlung von krebs
LTPA2017011I1 (lt) Antikūnas prieš PDGFR-alfa, skirtas naudoti auglių gydymui
EP1765391A4 (de) Bakterielle zusammensetzungen zur behandlung von krebs
EP1888786A4 (de) Verwendung freier zirkulierender dna zur diagnose, prognose und behandlung von krebs
EP2303463A4 (de) Superparamagnetische nanoteilchen zum entfernen von zellen, krankheitserregern oder viren
ATE532507T1 (de) Neramexane zur behandlung von subakuten tinnitus
DE602006018057D1 (de) Substituierte chinolone und verwendungsverfahren
IL200905A0 (en) Compounds and compositions comprising the same for use in treating hepatitis c
EP4091585C0 (de) Vorrichtung zur behandlung von refluxösophagitis
EA200970737A1 (ru) Оксабициклогептаны и оксабициклогептены, их получение и применение
ATE495179T1 (de) Tetrahydropyridothienpyrimidin-verbindungen und verwendung zur behandlung proliferativer erkrankungen
HRP20181727T1 (hr) Upotreba protutijela protiv čimbenika xi, namijenjena sprečavanju ili liječenju stvaranja krvnog ugruška
ATE481984T1 (de) Vakzine-peptid-kombinationen gegen katzenallergie
BRPI0819519A2 (pt) Análogos de triarilmetano e seus usos no tratamento de cânceres.
DE602006018193D1 (de) Vorrichtung zur behandlung schmutziger flüssigkeiten
DK2235002T3 (da) 4-pyridinonforbindelser og anvendelse heraf til behandling af cancer
NO20075368L (no) Antiinflammatoriske modaliteter
EP2173337A4 (de) Phosphaplatine und ihre verwendung bei der behandlung von gegen cisplantin und carboplatin resistenten krebserkrankungen
EP2249765A4 (de) Dapson zur behandlung von rosascea
NO20082425L (no) Formuleringer omfattende jorumycin-, reni-eramycin-, safracin- eller saframycin-relaterte forbindelser for behandling av proliferative sykdommer
EP1937319A4 (de) System zur behandlung mit ultravioletter strahlung
EP2029172A4 (de) Antikörper gegen c35 zur behandlung von krebs
EP1863520A4 (de) Verwendung von interleukin 17e zur behandlung von krebs
ATE450266T1 (de) Parapocken-viren in kombination mit klassischen zytotoxischen chemotherapeutika als biochemotherapie zur behandlung von krebs

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1951274

Country of ref document: EP